June 2018

New Product - Oncaspar

Pegaspargase (Oncaspar) is a modified (pegylated) version of the enzyme asparaginase, which cleaves the amino acid asparagine into aspartic acid and ammonia. Depletion of asparagine in blood serum results in inhibition of protein synthesis, especially in leukaemic blasts which are not able to synthesise asparagine, thus undergoing cell death. Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia. Oncaspar is contraindicated with a history of: serious thrombosis during previous asparaginase therapy; pancreatitis including pancreatitis related to previous asparaginase therapy; serious haemorrhagic events during previous asparaginase therapy; severe hepatic impairment. Oncaspar solution for injection (3750 units/5 mL) is available in a pack size of 1.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629